Zontivity

Active Ingredient(s): Vorapaxar Sulfate
FDA Approved: * May 8, 2014
Pharm Company: * MERCK SHARP DOHME
Category: Heart (Cardiac)

Vorapaxar (brand name Zontivity, formerly known as SCH 530348) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.[2] Contents 1 Medical uses 2 Contraindications 3 Drug interactions 4 Dose adjustment 5 Mechanism of action 6 Storage 7 History 8 References 9 External links Medical uses Vorapaxar is used for persons with a history of myocardial infarcti... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Zontivity 2.08 mg Oral Tablet, Film Coated

NDC: 0006-0351

Labeler:

Merck Sharp & Dohme Corp.

Zontivity 2.08 mg Oral Tablet, Film Coated

NDC: 66992-208

Labeler:

Wraser Pharmaceuticals, LLC

Zontivity 2.08 mg Oral Tablet, Film Coated

NDC: 70347-208

Labeler:

Aralez Pharmaceuticals Us Inc.